The emergence of drug-resistant pathogens such as staphylococci and enterococci in the hospital setting has long being recognized as a serious clinical problem. Staphylococcus aureus is the causative agent of many nosocomial infections from minor skin abscesses to serious, potentially life threatening diseases such as bone and soft tissue intra-surgical infections, sepsis and invasive endocarditis, while enterococci are responsible for nosocomial bacteraemia, surgical wound infections and endocarditis. The most infamous drug-resistant forms of these include MRSA (methicillin resistant S. aureus), VISA (vancomycin insensitive S. aureus), hVISA (heterogenous vancomycin insensitive S. aureus) and VRE (vancomycin resistant S. aureus). While enhanced hygiene awareness is essential to any solution, the identification of effective novel antimicrobial compounds remains a major goal in eradicating these and other infections caused by multi-drug resistant pathogens. In recent years a class of antimicrobial peptides, the Lantibiotics, have been the focus of an ever increasing level of attention. This interest has been prompted by an enhanced appreciation of the mode of action of these peptides (including, in many cases, the ability to bind lipid II) and their frequently high levels of antimicrobial activity. Here we review lantibiotic-related issues in drug discovery, outline the strategies that have been employed to identify these peptides and summarize the use of bioengineering to generate enhanced forms of these peptides as well as the application of the associated biological machinery to generate novel forms of existing pharmaceutical compounds. In so doing we highlight how some, or all, of these approaches have the potential to result in the development of clinically important drugs.
INTRODUCTION
The emergence of multidrug resistant pathogens has long been recognized as a significant issue in clinical healthcare. As a consequence of this phenomenon the first generation of antibiotics developed for clinical use has, for quite some time, been rendered ineffective and in response to selective pressures arising due to repeated exposure to an antibiotic, microbes have continued to evolve in response to the multitude of derivatives that have subsequently been generated. Although this trend reflects the situation with numerous microbial pathogens, Gram positive disease-causing nosocomial infection-associated microbes in general, and Staphylococcus aureus and Enterococcus sp. in particular, have attracted particular notoriety.
Methicillin Resistant Staphylococcus aureus (MRSA)
Staphylococcus aureus is one of the most frequently studied human pathogens and although it is present on the skin of healthy individuals without causing disease, it is responsible for a variety of infections, both nosocomially-and community-acquired. These range from minor skin abscesses to serious, potentially life-threatening diseases, such as bone and soft tissue intra-surgical infections, sepsis and invasive endocarditis [1] . Those at greatest risk of contracting S. aureus infections are patients whose immune system is compromised as a result of an underlying condition. The most common risk factors include frequent, prolonged stays in healthcare facilities, the presence of a chronic illness such as diabetes, cancer or HIV/AIDS, being very young or very old, frequent use of antibiotics, having an open wound, dermatitis or skin lesions, poor nutrition and poor hygiene. Patients who require catheterization, such as kidney dialysis patients or people with urinary catheters, are also at higher risk. Methicillin resistant Staphylococcus aureus (MRSA) i.e. strains that are resistant to all penicillins, including methicillin and related -lactamases, first emerged in 1961 [2] . All MRSA strains harbour the mecA gene, which encodes the low affinity penicillin-binding protein 2a (PBP2a). The production of this PBP confers resistance to otherwise inhibitory concentrations of -lactam antibiotics. mecA is carried on a mobile genetic element, SCCmec, which is integrated in the chromosome of S. aureus. Five different SCCmec types have been identified. MRSA typically cause infections of inpatients in health care facilities and *Address correspondence to this author at the Department of Microbiology, University College Cork, Cork, Ireland; Tel: +353 (0)21 4903146; Fax: +353 (0)21 4903101; E-mail: p.cotter@ucc.ie as a consequence have become known as health care associated MRSA, or HA-MRSA, and include SCCmec types I, II and III. Since the late 1990's MRSA infections have also been detected among the general population (community acquired MRSA, or CA-MRSA). While the initial presumption was that these infections were caused by HA-MRSA that had 'escaped' from health care facilities, it became apparent that the S. aureus strains responsible were genetically distinct from their HA counterparts with CA-MRSA strains possessing the more simple and less encumbering type IV (and to a lesser extent type V) allelic version of SCCmec [3] . It was also evident that these infections were specifically associated with previously healthy individuals (typically children and young adults) that lack traditional risk factors such as recent hospital admittance, surgery, or long-term residence in care facilities [4] . The spectrum of clinical infections caused by CA-MRSA has also tended to differ from that caused by HA-MRSA with CA-MRSA being predominantly isolated from skin and soft tissue infections such as abscesses, cellulitis, folliculitis and impetigo. Significantly, CA-MRSA infections can also be severe, e.g. necrotizing fasciitis and necrotizing pneumonia and thus can result in hospitalisation and even death. The presence of the type IV SCCmec enables CA-MRSA to survive sporadic exposure to the limited varieties of antibiotics prescribed in outpatient clinics but, in contrast to SCCmec types I-III, doesn't have a detrimental impact on its fitness/ability to grow successfully as part of the natural flora of healthy human beings. When first identified it was noted that CA-MRSA strains differ from their HA-MRSA equivalents in that antibiotic resistance in CA-MRSA strains was often limited to -lactam antibiotics only [5] . This is consistent with the absence of antibiotic resistance genes other than mecA [6] . While this fact suggested that these strains would represent less of a healthcare challenge than the HA strains, it quickly became apparent that the rapid growth (CA-MRSA grow much faster than HA-MRSA) [7] and increased virulence [8] of CA-MRSA meant that any delay in switching from the -lactam antibiotics normally used to treat infections of unknown aetiology could have very serious medical implications, including death. Significantly, these problems are now being compounded by the emergence of multidrug resistant forms of CA-MRSA [9] .
Coagulase Negative Staphylococci (CNS)
Though not the focus of as much attention as its S. aureus counterparts, methicillin resistant S. epidermidis (MRSE) can also be problematic. Coagulase negative staphylococci (CNS) such as S. epidermidis are particularly associated with infections arising from the use of intravascular catheters for both the diagnosis of and treatment of diseases in hospitals [10, 11] . CNS is the source of the majority of nosocomial bloodstream infections and of these, S. epidermidis is the most frequently isolated species as it is the causative agent of 74% to 92% of CNS related-hospital acquired bacteremia [12, 13] . The people at most risk of contracting such an infection are those undergoing chemotherapy, patients with indwelling central venous catheters, premature infants, patients receiving parenteral nutrition, recipients of bone marrow transplants with prolonged venous catheterization being the common risk factor [14] .
Enterococcus Sp.
Of Enterococcus sp., E. faecium and E. faecalis are most commonly isolated from the hospital environment [15] . Since the mid-to late 1970s it has been established that enterococci can cause hospital acquired infections and in the intervening period they have become the 2 nd most common organisms recovered from nosocomial urinary tract and wound infections and the third most common cause of bacteremia in the US [15] . The predominant explanation for the ability of these microorganisms to become established and survive in a hospital setting is due to their resistance to several commonly used antibiotics. Such resistance is frequently acquired through the receipt of foreign genetic material due to the transfer of plasmids and transposons. As a consequence of this phenomenon, resistance to vancomycin and related glycopeptides antibiotics was first observed in Enterococci.
Vancomycin Resistance
In recent years the frequency with which MRSA (and MRSE) have been isolated has increased greatly, resulting in an ever-greater reliance on what has been known as 'the drug of last resort', the glycopeptide antibiotic, vancomycin, and the closely related, teicoplanin. These compounds possess antimicrobial activity by virtue of an ability to bind lipid II, the essential building block required for peptidoglycan, and therefore cell wall, synthesis [16, 17] . To fully appreciate the consequences of lipid II binding one needs to appreciate the role of lipid II in peptidoglycan/cell wall formation. The cell wall of bacteria comprises a polymer of alternating amino sugars, Nacetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). These glycan polymer chains are cross-linked by a pentapeptide typically with the sequence L-alanyl--D-glutamyl-diamino-pimelyl (rLlysyl)-D-alanyl-D-alanine that is attached to the carboxyl group MurNAc sugar. These subunits are assembled in the cytosol on the membrane-anchoring carrier, undecaprenyl phosphate, yielding lipid II. It is the presence of this cross linkage that gives the bacterial cell structural rigidity and mechanical strength [18] . The assembly of the cell wall subunit begins on the cytoplasmic side of the plasma membrane of the cell. Peptidoglycan synthesis is brought about by two lipid-bound intermediates. Firstly, lipid I is formed by the transfer of the phospho-MurNAc-pentapeptide group from the UDP-MurNAc group to the membrane bound lipid carrier undecaprenylpyrophosphate. The second intermediate, lipid II, is formed when the UDP-N-acetylglucosamine (UDP-GlcNAc) residue couples with to the UDP-MurNAc group of lipid I [19] . The lipid II then contains the complete peptidoglycan subunit linked via a pyrophosphate to the membrane-embedded polyisoprenoid anchor. Lipid II is subsequently translocated to the periplasmic or exterior side of the plasma membrane by means of a mechanism that is not yet known [18] .
Vancomycin, derived from Norcardia orientalis (formerly Streptomyces orientalis) [20] , is active against most Gram positive bacteria including Streptococci, Staphylococci, Corynebacteria, Clostridia, Listeria and Bacillus species [21] . It specifically targets the Cterminal D-Ala-D-Ala of the pentapeptide of lipid II and in so doing blocks the binding of penicillin binding proteins (PBPs) that are necessary for the polymerization and integration of the lipid II subunits into the cell wall. This in turn culminates in cell death as cell wall synthesis is inhibited [22] . However, resistance to vancomycin is being observed with ever-increasing frequency. Initially vancomycin resistance was identified in enterococci. In the case of resistance to glycopeptides, resistance first emerged as a consequence of the acquisition of a transposon carrying a unique set of genes for vancomycin resistance, and the vanA gene in particular, which results in the conversion of the D-Ala-D-Ala vancomycin-binding site of the lipid II pentapeptide to D-Ala-D-Lac, thereby preventing vancomycin binding [15, 23] . In the interim, six vancomycin resistance determinants, VanA, VanB, VanC, VanD, VanE and VanG [24] [25] [26] have been identified. Five of these types (VanA, B, D, E, and G) correspond to acquired resistance, with only one type (VanC) being an intrinsic property of enterococci (E. gallinarum, E. casseliflavus and E. flavescens) [27, 28] . VanA resistant strains have a considerably high level of resistance to vancomycin and teicoplanin boasting MICs of 64μg/ml and 16 μg/ml [24] . The levels of vancomycin resistance of the VanB producing isolates varies (4 to 1000 μg/ml) and these remain susceptible to teicoplanin. VanB resistant determinants are located on large mobile genetic elements that can be transferred between enterococci [29, 30] . The VanC resistant phenotypes exhibit low level resistance to vancomycin with MICs of 4 to 32 μg/ml and susceptibility to teicoplanin is maintained [15] . VanD type-resistance is acquired as a result of constitutive petidoglycan production with the precursors ending in D-Ala-D-Lac. An unusual feature of these vanD strains is that they possess only slightly diminished activity to teicoplanin (MIC, 4 g/ml) despite the presence of D-Ala-D-Lac precursors [31] . VanD resistance in not transferable by conjugation to other enterococci [32] . VanE phenotype corresponds to low-level resistance to vancomycin and maintains susceptibility to teicoplanin as a result of the peptidoglycan precursors terminating in D-Ala-D-Ser, as in intrinsically resistant Enterococcus species [31] . Strains that have acquired VanG are resistant to low levels of vancomycin (MIC, 16 g/ml) and have susceptibility to teicoplanin (MIC, 0.5 g/ml) [33] . These also produce precursors with D-Ala-D-Ser at the end [31] .
The transfer of the vanA gene resistance determinants from VRE to S. aureus by cell-to-cell mating was first demonstrated in the laboratory [34] , an occurrence which was subsequently reproduced in the hospital setting. Fortunately, to date, vancomycin resistant S. aureus (VRSA) have been extremely rare but they do appear to be on the increase [35] . The first VRSA isolates identified, in the U.S.A, were discovered in Michigan [36, 37] , Pennsylvania [38] and New York [39] (see [40] for review). In the first two cases, it seems that the VRSA strains developed resistance during a prolonged course of vancomycin therapy. VRSA strains have been reported in Jordan [41] , Brazil [42] and more recently, two from India (although in the latter case the vanA gene was not detected) [43] .
However, the ever-greater reliance on vancomycin has resulted in a more immediate problem i.e. the spread of heterogenous vancomycin insensitive S. aureus (hVISAs) and vancomycin insensitive S. aureus (VISAs). Although not as vancomycin-resistant as VRSA (minimum inhibitory concentration of 32 g/ml), VISAs (requiring vancomycin concentrations of 8 to 16μg/ml for inhibition [44] ) have been more frequently encountered while hVISA strains require a vancomycin MIC of 1 to 4μg/ml. VISA strains emerge as a consequence of adaptation resulting from exposure to the glycopeptide rather than acquisition of additional genetic elements and are characterised by having lower growth rates and thicker cell walls than fully susceptible strains [45, 46] . The first clinical isolate with reduced susceptibility to vancomycin was the Mu50 strain [47] . It was found to contain 30-40 layers of peptidoglycan in its cell wall, which contrasts with a more typical 20 layers. This phenomenon has subsequently been found to be typical of VISA strains in general. In fact, it has been deduced that cell wall thickness contributes to resistance by sequestering molecules of vancomycin in the cell wall peptidoglycan/reducing its access to lipid II, and hence reduces the susceptibility of these S. aureus strains to vancomycin. In a study conducted by Cui et al., it was established that cell wall thickening contributes to resistance by reducing the diffusion coefficient of vancomycin penetration through the cell wall peptidoglycan layers [21] . hVISA strains were found to produce three to fivefold greater levels of penicillin binding proteins (PBPs) 2 and 2' and three to eight fold higher quantities of cell wall precursors than vancomycin susceptible strains did [48] . It is noted that cell wall thickening accompanied with increased MICs was a common phenotype observed with VISA strains. Several countries have reported incidences of S. aureus with intermediate resistance to vancomycin [49, 50] . As a consequence of the emergence of resistance to vancomycin, formerly known as 'the drug of last resort' with respect to Gram positive nosocomial pathogens, the discovery of new alternative measures for the control, and ultimately, the eradication of MRSA and other multidrug resistant Staphylococci has become more pressing.
New Anti-Staphylococcal and Anti-Enterococcal Antimicrobials
Therapeutic agents such as daptomycin, tigecycline, linezolid, and quinupristin/dalfopristin have been developed to treat more severe infections that do not respond to glycopeptides (see [51] for review). Daptomycin is a fermentation product of Streptomyces roseosporus [52] and is a potent inhibitor of Gram positive pathogens [53] . It is administered intravenously due to its large size which prevents absorption across the gastrointestinal tract. Its mode of action involves insertion into and disruption of the plasma membrane [52] . Tigecycline belongs to a class of new agents called glycylcyclines which are derived from tetracyclines and were generated specifically to deal with bacteria resistant to the earlier generation tetracyclines [54] . Tigecycline, the first in this particular class, is active against both Gram-positive cocci, including MRSA [55, 56] and Gramnegatives such as the Enterobacteriaceae. Tigecycline is generally used to treat complicated intra-abdominal and skin soft tissue infections [57] . Linezolid (Zyvox) is the first of a new class of a newly developed group of anti-Gram positive antibiotics known as the oxazolidinones [58, 59] . It has a unique mode of action, targeting the bacterial 50S ribosomal subunit to block protein synthesis [58, [60] [61] [62] . Since linezolid became available in 2000, clinical isolates of VRE and MRSA resistant to linezolid have been reported [63] [64] [65] [66] [67] while Gram negative bacteria appear to be resistant to linezolid as a result of an endogenous efflux [58, 60, 68] . Quinupristin/dalfopristin (Synercid) is a new water soluble antimicrobial agent comprising of quinupristin and dalfopristin, which are semi-synthethic antibiotics of streptogramin groups B and A respectively [69] and is required in a ratio of 30:70. The in vitro spectrum of activity includes most Gram positive aerobes, significant Gram negative aerobes, Gram positive anaerobes and intracellular bacteria that are responsible for a range of infections [59] . It inhibits bacterial protein synthesis by binding of each component to a different site on the 50S subunit of the bacterial ribosome, dalfopristin leading to a conformational change in the ribosome which increases the affinity of the ribosome for quinupristin. Each of the two streptogramins separately acts as a bacteriostatic agent but in combination they are bactericidal [70] . Quinupristin/dalfopristin is available only as an intravenous product. Quinupristin/dalfopristin is active against multidrug resistant strains of S. aureus, S. epidermidis and E. faecium thus encouraging potential use of this combination in the treatment of infections caused by such problematic drug resistant Gram positive pathogens [69, [71] [72] [73] .
New Lipid II-Targeting Antrimicrobials
Despite the availability of these drugs, the options available to clinicians when treating infections caused by multidrug resistant pathogens are limited. Therefore, the continuing identification and development of novel antibacterial substances is of the utmost importance. As pointed out above, given the effectiveness with which pathogens are inhibited as a consequence of the sequestering of lipid II, there is obviously merit in focusing on antimicrobials that bind lipid II and which are not impacted upon by the consequences of pentapeptide modification. Ramoplanin is a lipoglycodepsipeptide [74] , identified as a result of screening the metabolites of Actinomycetes spp., which has the capacity to bind to the lipid II pentapeptide region regardless of modifications and is functionally related to the lantibiotic class of antimicrobials [74] . Ramoplanin is a promising candidate for treatment of Gram positive bacterial infections, in particular infections caused by Gram positives that are resistant to glycopeptides, macrolides and penicillins and has already reached phase III clinical trials. Binding studies performed using short variants of lipid II revealed that ramoplanin is capable of binding any variant of lipid II given that contains a pyrophosphate cage [75] . Derivatives of vancomycin which do not require the presence of D-Ala-D-Ala in the lipid II pentapeptide have also been developed [18] . These include the semisynthethic dalbavancin [76] , televancin [77] and oritavancin [78] . Televancin and other such derivatives exhibit superior in vitro activity compared to that of vancomycin [79] [80] [81] which results from the addition of a hydrophobic moiety to the dissacharide functionality of vancomycin. As a consequence of these derivatizations these antimicrobials have been named lipoglycopeptides. Televancin is in the late stages of clinical development trials for the treatment of serious Gram-positive infections. It has at least two modes of action in MRSA in that, like the prototype vancomycin, it too binds the D-Ala-D-Ala site of peptidoglycan but it has also been reported to disrupt the bacterial membrane. Upon exposure to televancin, an increase in cell permeability was observed and leakage of cellular ATP and K + was evident [22] . Oritavancin inhibits bacterial cell wall formation by blocking the transglycosylation step in peptidoglycan biosynthesis in a substrate-dependent manner. The effects of oritavancin on cell wall synthesis are attributable to interactions with dipeptidyl residues of peptidoglycan precursors. Unlike vancomycin, however, oritavancin is strongly dimerized and can anchor to the cytoplasmic membrane due to the presence of an alkyl side chain. Oritavancin is consistently active against enterococci and staphylococci. Dalbavancin is in late stage clinical development. A phase II study highlighted the efficacy of dalbavancin against catheter related bacteremia and other studies (both in vivo and in vitro) have resulted in the potential application in infections such as endocarditis, respiratory tract infections [82] and skin structure infections [83] .
Two explanations have been proposed to explain the ability of these agents to inhibit vancomycin resistant bacteria, both of which involve effects on the late stages of cell wall peptidoglycan synthesis that take place at the exterior surface of the bacterial cell membrane [77] . One suggested mechanism is that the hydrophobic substituents of lipoglycopeptides possess strong dimerization and membranedocking properties that bring about enhanced binding affinities for peptidoglycan intermediates at the target site in bacteria [84] [85] [86] [87] . The second mechanism thought to be involved is that the liposaccharide elements of lipoglycopeptides interact directly with the transglycosylase enzymes that are responsible for the polymerization of precursors into immature, un-crosslinked peptidoglycan [88] [89] [90] . While these derivatives are likely to represent the next step forward with respect to antimicrobial chemotherapy, there exists a large family of antimicrobial peptides, many of which target lipid II in a distinctive way, that have been the focus of ever-greater attention. These are the lantibiotics.
LANTIBIOTICS
Lantibiotics are ribosomally synthesized antimicrobial peptides which are produced by Gram positive bacteria and are active predominantly against other Gram positive bacteria. Their biosynthesis requires post translational modification resulting in the presence of unusual and rare amino acids such as lanthionines, hence the name Lanthionine-containing antibiotics [91] . Lantibiotics have being investigated since 1928 when nisin (although not named as such at this time) was first described to have activity against Streptococcus lactis (now Lactococcus lactis) in fermentation cultures [92] . Nisin is routinely used by the food industry as a preservative due to its activity against a wide range of bacterial pathogens. Despite, or possibly because of, the success of nisin in the food industry, lantibiotics have until recently not been viewed as antimicrobials that could be applied to a clinical setting [93] . However because these naturally occurring peptides, frequently synthesized by generally regarded as safe bacteria such as lactic acid bacteria, have not yet been used in the clinical setting or on the same scale as antibiotics developed by the pharmaceutical industry, an existing resistant population does not exist. Another interesting feature of lantibiotics that makes them attractive candidates from a drug discovery perspective is that they are small peptides. This is also probably one of the reasons they are not routinely identified during large scale screening strategies. Despite this, an ever greater number of lantibiotics are being identified, many of which possess potent antimicrobial activities. Furthermore, due to their small size (and gene-encoded nature) they are excellent candidates for derivatization, either chemically or genetically, with a view to increasing antimicrobial activity and/or widen the spectrum of bacteria against which they are effective [94, 95] . The aim of this review is to highlight the efficacy of lantibiotics against problematic pathogens and outline their potential as antimicrobials in clinical settings.
POST-TRANSLATIONAL MODIFICATION
The fact that lantibiotics are ribosomally synthesized makes them quite unique. Following synthesis of the unmodified form of the structural peptide, it is subjected to extensive post translational modification to form the biologically active peptide [95] [96] [97] . In addition to the lanthionine (Lan) and methyllanthionine (MeLan) structures which give these peptides their name, many other atypical amino acids generally not found in nature can be present including, most frequently, 2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb) which result from the dehydration of serine and threonine residues, respectively [97, 98] . The thiother Lan is formed when the double bond in Dha is attacked by the thiol (-SH) group of a neighbouring cysteine residue [99] while MeLan results when the aforementioned reaction involves Dhb (Fig. 1) . Due to the formation of these intramolecular bridges, frequently linking otherwise relatively distantly-located amino acids, lantibiotics are polycyclic in structure. Fig. (1) . The presence of these cyclic rings increases the rigidity of the peptide [100] and contributes to their tolerance to proteolytic degradation and thermal stress. It has also been suggested that the change in chirality of one of the two alpha carbons involved contributes to the activity of the compounds [101] .
CLASSIFICATION
A number of lantibiotic classification systems have been proposed. In 1991, Jung classified lantibiotics into two groups; type A and type B peptides, based on their structure and functional aspects. Type-A lantibiotics were classified as those which are elongated, amphiphilic, screw shaped membrane depolarizing, cationic peptides up to 34 residues in length and are similar with respect to the arrangement of their (Me-)Lan bridges. These peptides, which included nisin, subtilin, pep5 and epidermin, were thought to act primarily by disrupting the integrity of the cell membranes of target organisms by the formation of pores. In contrast, type-B lantibiotics were those that were more globular in structure, up to 19 residues in length and active through inhibiting enzymatic functions and, more specifically, impact on cell wall synthesis by binding to membrane lipids. Members of this group include mersacidin, actagardine, and the duramycins. However, in the last decade a greater understanding of the mode(s) of action of these peptides, coupled with the discovery of new lantibiotics with intermediate features, have made classification on the basis of structure and function more difficult.
In 2005, classification of lantibiotics was again revisited and the peptides were subgrouped on the basis of similarities in their amino acid sequence [102] 11 subgroups were proposed, each named to reflect the prototypical example in each case i.e. the nisin-, epidermin-, streptin-, Pep5, lacticin 481-, mersacidin-, LtnA2-, cytolysin-, lactocin S-, cinnamycin-and sublancin-like peptides. Here we extend this list to 12 to accommodate the identification of the novel lantibiotic planosporicin ( Table 1) . Taking the lacticin 481 group as an example to demonstrate the basis of this system, it is evident from alignment of the unmodified amino acid sequences of the peptides within this group (such lacticin 481, lacticin J46, mutacin II, butyrivibriocin, ruminococcin, streptococcin SA-F22, nukacin, variacin and a number of salvaricins) that a number of conserved residues exist. All of the A1/ components of the two component lantibiotics identified Fig. (1) . The post-translational modification common to all lantibiotics is the formation of ( methyl) lanthionine bridges. This involves the initial dehydration of serine and threonine residues to dehydroalanine and dehydrobutyrine, respectively, followed by the an interaction with cysteine.
to date, with the exception of cytolysin, fall into the mersacidin category. Alignment of the peptides within the mersacidin and lacticin 481 groups (which together make up more than 40% of all lantibiotics described to date) reveals a number of conserved residues that may represent essential core amino acids in the structure-function relationship of these peptides [103] . Even more recently [104] a division of lantibiotics into three classes has been proposed (Class I, II or III) which is based on the pathway by which the peptide is modified and also by the presence or absence of antimicrobial activity. This categorization is based on a scheme that was proposed previously [91] , is quite flexible and can be used in combination with the approach of Cotter et al. [102] and will allow for the introduction of future lantibiotics that are yet to be discovered and characterized into this scheme. This description takes into account a number of differences/diversities amongst the lantibiotics such as, differences in the leader peptide sequence, the function of the peptide and biosynthetic operon structure. Class I lantibiotic prepeptides are modified by 2 distinct enzymes, LanB and LanC. The LanB enzymes are responsible for the dehydration of the threonine and serine residues with the associated LanC enzyme being responsible for cyclization. The peptide is then exported by an ABC transporter, LanT while a stretch of N-terminally located amino acids, constituting the leader peptide, is cleaved by subtilisin-like serine proteases designated as Lan P. Members of this class include nisin, subtilin, epidermin and Pep5. In contrast, lantibiotics belonging to Class II possess only a single large enzyme to carry out dehydration and cyclization duties i.e. the LanM enzymes. LanM shares no similarity to LanB proteins, but shares slight homology with LanC proteins across its C-terminal domain including three conserved zinc binding ligands [105] . Secretion of class II lantibiotics is also carried out by a single multipurpose protein that boasts a conserved N-terminal cysteine protease domain [91] . Despite the difference in the exporters of class I and class II lantibiotics, they are both designated as LanT proteins. The class II lantibiotics include the two component lantibiotics. To date, there has only been seven of such peptides been elucidated namely lacticin 3147 [106] , staphylococcin C55 produced by S. aureus C55 [107] , haloduracin [108, 109] , Smb produced by Streptococcus mutans [110] , cytolysin [111] , plantaricin W produced by Lactobacillus plantarum [112] and BHT-A produced by Streptococcus rattus BHT [113] which are distinctive by virtue of the fact that two lanthioninecontaining peptides function synergistically to bring about optimal antimicrobial activity. In the majority of cases each structural peptide, encoded by a corresponding structural gene, is modified by a different LanM enzyme [108, 114] , though cytolysin is exceptional in possessing only one LanM enzyme, a fact which reflects the high similar nature of the two structural peptides in this case. In all cases one LanT protein removes the leaders and secretes the modified peptides. It should be noted that lactocin S is unusual in that it possesses features associated with both class I lantibiotics (i.e. possession of lanP and T genes) and class II (i.e. possession of a lanM gene) lantibiotics [91] . Here we place greater emphasis on the presence of a lanM homologue, and thus locate the peptide within the class II section ( Table 1) .
In this newly devised/revised classification format, a third and novel class is suggested. These are lantibiotics that lack any noteworthy antimicrobial activity and thus, although lanthionine-containing, lack the antimicrobial activity which the name lantibiotic implies. Up to now, three such peptides have been described, they are SapB, SapT and AmfS which are produced by Streptomyces coelicolor, Streptomyces tendae [115] [116] [117] and Streptomyces griseus [118] respectively ( Table 1) . It has previously been noted that streptomycetes are known to produce lantibiotic peptides that have activity against Gram positives, two of which are cinnamycin [119] and duramycin [120] .
Mode of Action -Nisin
As mentioned previously, some lantibiotics are active by virtue of binding to lipid II, the essential precursor in cell wall biosynthesis. Nisin binds the pyrophosphate moiety of lipid II [121] via two of its N-terminal rings with five intramolecular hydrogen bonds being in- 
volved. By binding this lipid II precursor, it makes it unavailable to be transported to a developing cell wall and as a result, hampers the formation of the bacterial cell wall. Binding of lipid II also facilitates the pore formation process, during which four nisin molecules form the pore complex, generating a pore with a diameter of 2nm [122] . Fig (2) . This permeabilization of the membrane causes dissipation of vital ions and small metabolites and ultimately results in the dissipation of the proton motive force (PMF) leading to the cessation of all metabolic and biosynthetic processes and eventually cell death [123] [124] [125] . It has been established that the formation of pores takes milliseconds [126] and that cell death occurs within minutes [124] . While the N-terminus of nisin is important for the interaction with lipid II, mutation of the hinge region (which links the N-and C-termini) and C terminus impacts on pore formation [127, 128] . Apart from being able to inhibit cell wall synthesis and bring about pore formation, nisin and the related cationic lantibiotic Pep5 have been shown to possess a further mode of action, that is, the induction of autolysis of susceptible staphylococcal strains [22] . This causes massive cell wall degradation of the septa between dividing cells. The peptides have the ability to release two cell wall hydrolysing enzymes that are highly cationic and which under normal circumstances bind via electrostatic interactions with the negatively charged acids in the cell wall such as teichoic and teichuronic acids. Such tight binding renders the autolysins inactive. However the cationic nature of nisin and Pep5 brings about the displacement of these enzymes leading to their activation and rapid cell lysis [129] . Nisin, and other lantibiotics that possess a nisin-like N-terminal pyrophosphate cage also uncouple cell wall synthesis and membrane synthesis during cell division [22] . During cell division, large amounts of petidoglycan are synthesized at the septum and during cell elongation, peptidoglycan synthesis is organized in helical threads along the longitudinal axis of the cell [130] . This is apparent from the localization of lipid II in vivo at the septum of Bacillus subtilis and in helical threads along the long axis of this bacterium, as previously seen with fluorescently labeled vancomycin [130] . If lipid II cannot co-localize with peptidoglycan synthesis, then cell wall formation is inhibited and bacteria are killed. Hasper et al. tested for lantibiotic-induced lipid II segregation in bacteria by using fluorescently labeled vancomycin in vivo as a marker [130] . After the addition of fluorescently labeled nisin it was apparent that the lipid II distribution pattern was indeed altered. Rather than observing fluorescence at the septum and within helical threads, fluorescence instead appeared to be clustered in patches along the bacterial membranes. This was observed for more than 80% of the bacteria [22] . Based on these experiments, it is deduced that nisin, and at least 10 other lantibiotics that possess a nisin-like N-terminal domain [99, 131] displace lipid II from its functional location in Gram positive bacteria.
Mode of Action -Epidermin
Epidermin is produced by S. epidermidis Tü 3298 [132] comprising of 22 amino acids [133] . Its structural analog, gallidermin, is produced by S. gallinarum Tü 3928 and differs from epidermin at position 6 of the N-terminal part of the molecule by having a leucine rather than an isoleucine residue [134] . Like nisin, epidermin can interact with, lipid II [124] , a phenomenon which is not surprising when one considers that the N-terminal double ring system in nisin and epidermin is almost totally conserved [121] . However, with the exception of this domain, there is very little structural similarity between the two peptides. Ring C, present in nisin, is absent in epidermin, epidermin possesses a much longer flexible hinge region and the C-terminal tail, which is required to carry out pore forming activity, is also completely missing from epidermin [135] . Instead its C-terminus is quite compact as a result of a double ring system involving an aminovinyl cysteine residue resulting from the oxidative decarboxylation of the terminal ring [136] . The solution structure elucidated by Hsu et al. reported that epidermin is an amphiphilic screw-shaped molecule with an overall length of 30Ä which is shorter than nisin that has a size of 50 Ä [121] . This structural feature explains why the ability of epidermin to form pores is strain specific, being dependent on the length of membrane phospholipids. Thus epidermin forms pores in Micrococcus sp but not Staphylococcus sp. [135] . The ability to form pores is not necessarily the over-riding factor with respect to specific activity determination as although epidermin does not appear to form pores in Lactococcus lactis, it is more potent than nisin against this strain [135] . Lipid II also appears to be the target for mutacin 1140, a member of the epidermin subgroup of lantibiotics [22] .
Mode of Action -Pep5
Pep5 is a 34 amino acid lantibiotic produced by S. epidermidis 5 that contains three ( -methyl)lanthionine bridges [137] , has a molecular mass of 3,488 Da and is strongly cationic [138] . Pep5 is positively charged due to the presence of six lysines and two arginines. All lysine residues are located on one side of the molecule with hydrophobic residues on the other side, therefore conferring an amphipathic nature to the peptide which facilitates pore-formation. With respect to pore formation, the hydrophilic side is thought to face the lumen of the pore while the hydrophobic part interacts with the membrane [139] with the ultimate consequence being that charged ions, amino acids, small metabolites and ATP rapidly leak from treated cells with a simultaneous drop in membrane potential [140] and a complete cessation of macromolecular biosynthesis [141] .
Mode of Action -Plantaricin C
Plantaricin C is a lacticin 481-like lantibiotic produced by Lactobacillus plantarum LL41 that has been shown to exert a potent bactericidal effect on several Gram positive strains including food pathogens and spoilage bacteria [142] . The N-terminus of plantaricin C is highly positive and contains a compact C-terminus with a ring arrangement similar to the mersacidin lipid II binding motif (see below; [143] ). It functions by dissipating the PMF of the bacterial target cell causing a loss of intracellular molecules such as glutamate and ATP which are necessary for the maintenance of metabolic processes within the bacterial cell [142] . More recently, an investigation into the mode of action of plantaricin C found it to be an inhibitor of cell wall synthesis through formation of a complex with the cell wall precursor lipid II. Although it shares a putative lipid II binding site with mersacidin, which only binds lipid II (see below), plantaricin C also forms a stable complex with lipid I, a trait it shares with nisin, thus indicating that two lantibiotics, nisin and plantaricin C, target the same structures on lipid II. As the lipid II binding motif that enables nisin to interact with lipid I/lipid II is not present in plantaricin C, additional linking sites, apart from the lipid II binding motif that it shares with, must be present. It may be that the presence of a highly positively-charged N terminus, which is absent from mersacidin, is significant.
Although plantaricin C has the potential to form pores, very high concentrations were required to bring about the mediation of pores in Micrococcsus flavus and pores were not formed when PlnC was unable to achieve cell permeabilization in L. lactis implying that the pore forming activity of plantaricin C could be strain specific and the lack of susceptibility of some strains could be linked to the absence of this pore forming activity [143] .
Mode of Action -Mersacidin
The class II prototypical mersacidin-like lantibiotic i.e. mersacidin is produced by a Bacillus sp. strain HIL Y-85, 54728 [144, 145] . It has a molecular weight of 1, 824 [146] . It is a single peptide lantibiotic made up of 20 amino acids [146] eight of which undergo modification to form intramolecular methyllanthionine rings [144] . It has no net charge, is very hydrophobic and is the smallest lantibiotic to have been identified to date. Mersacidin binds also lipid II [147] Fig. (3) however as the binding site of mersacidin on lipid II appears to include the GlcNAc amino sugar, mersacidin does not interact with, or bind, the lipid I precursor [19] . Nonetheless this activity is equally effective with respect to blocking the access of transglycosylase to its substrate. This activity was apparent following the treatment of staphylococci with mersacidin, which results in an extreme reduction in the diameter of the cell wall of the target cells, gradually causing cell lysis and ultimately cell death [144] . The binding of lipid II involves a distinct domain (GxxxxTxs/tCd/Ec (3-10x)C) that appears to be shared between mersacidin-and lacticin 481-like peptides [103] . The binding of this domain to lipid II involves a conformational change [148] and is probably reliant on movement around a hinge region that is located between two lanthionines rings (at residues 12 and 13 in the case of mersacidin) [148] . In contrast to nisin, mersacidin and related one peptide lantibiotics lack the ability to form pores. However, two-component lantibiotics that consist of one mersacidin-like peptide benefit from the presence of a second, synergistically-acting peptide that facilitates pore-formation.
Mode of Action -Lacticin 3147
This two component lantibiotic is produced by Lactococcus lactis subsp. lactis DPC3147 which was isolated from an Irish kefir grain [106] . Its two components, and , have molecular masses of 3306 and 2847, respectively. In the case of the two component lantibiotic, lacticin 3147, two components act synergistically to produce antibiotic activity at nanomolar concentrations. The mersacidin-like Ltn peptide (formerly LtnA1) binds initially to lipid II. This event is probably followed by insertion, to a certain extent, of the peptide into the bilayer. This triggers a conformational change in the peptide where a high affinity binding site is generated for the Ltn peptide (formerly LtnA2) and pore formation then occurs [143] . Although both peptides are required for optimal activity, the globular peptide displays a mersacidin-like ability to inhibit cell wall synthesis.
Mode of Action -Cinnamycin
All lantibiotics of the cinnamycin subgroup (duramycin, duramycin B, duramycin C, cinnamycin and ancovenin) contain one Lan and two MeLan structures and an identical bridging pattern. All of the cinnamycin like peptides, with the exception of ancovenin, also possess an unusual lysoalanine bridge that connects the C terminus with a Dha at position 6 and contain a single residue of hydroxyaspartic acid [149] [150] [151] . This particular group of lantibiotics displays a restricted antibactericidal activity, targeting only a few bacterial strains and Bacillus sp. in particular, impairing ATP-dependant protein translocation [152] and interfering with calcium uptake [153] . Duramycin has also been proven to block the transport of chloride [154] , sodium and potassium [155] and inhibit the proton pump of clathrin-coated vesicles [156] . However, cinnamycin (and duramycin) are better known as immunopotentiator peptides [157] which functions through the inhibition of phospholipase A2 by binding the phosphatidylethanolamine (PE) or lysophosphophatidylethanolamine (lysoPE) of the phospholipid moiety of the cell membrane [158] . The binding of the PE moiety of the lipid bilayer can also result in the induction of erythrocyte hemolysis [159] or interfere with prostaglandin and leucotriene biosynthesis [160] .
ACTIVITY OF LANTIBIOTICS AGAINST GRAM POSI-TIVE NOSOCOMIAL PATHOGENS Nisin
As noted above, nisin is routinely used in the food industry for preservation purposes in order to prevent spoilage of food products by pathogenic organisms [93] . It has also been shown to harbor contraceptive efficacy in two instances [161, 162] . However, it also possesses traits which indicate that it, or derivatives thereof, could be applied to the inhibition of drug resistant nosocomial pathogens.
Nisin is 3.4kDa amphipathic peptide produced by Lactococcus lactis strains and consisting of 34 amino acids. To date 4 natural variants of nisin have been identified i.e. nisin A, Z, Q and U, with nisin A and Z being the focus of the majority of research. Nisin Q is produced by L. lactis 61-14 and differs from nisin A by just four amino acids in the mature peptide and by two in the leader sequence [163] . Streptococcus uberis is a causative agent of bovine mastitis, however the S. uberis 42 strain was found to produce a lantibiotic, nisin U, which is 78% identical to nisin A [164] . Nisin A and nisin Z differ at position 27, with nisin Z having an asparagine residue at this location and nisin A having a histidine [165] , and their activity spectra are 83% similar [166] .
One of the most extensive investigations was carried out in 1998 when the efficacy of nisin against 56 multi-antibiotic resistant isolates of Streptococcus pneumoniae, 33 Staphylococci, including MRSA and coagulase negative strains, and 29 isolates of VRE (both E. faecalis and E. faecium) were tested [167] . Susceptibility to nisin was tested by treating exponentially growing cultures of the strains with nisin while MICs were established using the agar dilution method. Of the S. pneumoniae strains, all bar 6 underwent rapid lysis after a 20 minute exposure period to a 1mg/ml concentration of nisin. The remaining six were subjected to a longer exposure period of 60 mins where massive lysis was then observed. With respect to staphylococci, in the majority of cases a 10 4 fold drop in viable titre was evident after a 3 hour exposure to nisin at 37ºC and a significant reduction of optical density was also reported. All VRE strains suffered a 10 4 fold reduction in viable titre following treatment with a 10-20mg/ml concentration of nisin for a period of 4 hours. Thus the potent bactericidal effect of nisin against a selected number of the most prominent multidrug resistant Gram positive pathogens is evident. Worryingly, however, serial exposure of a penicillin-susceptible strain of S. pneumoniae to nisin (1 mg/L) in liquid culture resulted in the rapid appearance of stable nisin-resistant mutants in which the MIC increased from 0.4 to 6.4 mg/L and the resistance trait was transferable by genetic transformation [167] . The activity of nisin was investigated both in vitro and in vivo (in a mouse model) against Streptococcus pneumonia [168] . Nisin displayed excellent in vitro activity ( 0.25 mg/L in all cases) against clinical isolates of S. pneumoniae, some of which were resistant to penicillin, erythromycin, chloramphenicol and tetracycline but not vancomycin [168] . Significantly, although the MICs of nisin and vancomycin produced a similar MIC for S. pneumoniae, nisin was 8-16 times more active in an intravenous two-treatment nisin regimen [168] . This two dose treatment is required as nisin only had a serum half-life in mice of 0.9 hours and therefore two doses are necessary for optimal activity. Low blood and tissue levels of nisin are adequate to prevent death in infected mice as a result of the rapid bactericidal action of nisin [168] .
A related, applied study investigated if this antimicrobial activity could be utilized to reduce the attachment of pathogens to catheters as the use of central venous catheters can be the source of a number of infections that have serious consequences such as medical complications and prolonged stay in the hospital setting [169] . The data to date is positive as nisin has been found to have the ability to adsorb to surfaces and prevent bacterial attachment [170] and it was established that S. aureus, S. epidermidis and E. faecalis were inhibited in/on catheter tubing that had been treated with nisin [171] .
The effectiveness of nisin against enterococci and staphylococci was also evident in subsequent deferred antagonism agar-based assays [166] which also established that nisin A and Z are inhibitors of Mycobacterium smegmatis (ATCC 35797 and ATCC 35758), with nisin Z being the more efficient of the two [166] . M. smegmatis are non-pathogenic fast-growing mycobacteria frequently used for antimicrobial activity assays to indicate the likelihood that an antimicrobial has activity against pathogenic mycobacteria (such as M. tuberculosis and M. leprae). Anti-Clostridium difficile data has also been impressive. This is of clinical relevance as Clostridium difficile-associated diarrhea (CDAD) is the causative agent of the majority of cases of hospital acquired diarrhea and is responsible for gastroenteritis infections in nursing homes. It can occur sporadically or in clusters and poses a major threat clinically [172] . One of the most common factors with individuals suffering from CDAD is the predisposition to antibiotic therapy. The current treatments for CDAD are oral metronidazole and vancomycin [173] but recurrence rates range from 2 to 38% for metronidazole and 8 to 50% for vancomycin [173] . Of the two, metronidazole is often the preferred option because of fears of gut colonization by VRE [174, 175] , or because of the risk of further enhancing the emergence of vancomycin resistant bacteria in the hospital setting. In some instances, metronidazole resistance in C. difficile has been reported [176] . The in vitro MICs of these routinely used drugs and nisin with respect to sixty toxigenic strains belonging to different phage types, isolated from subjects presenting with antibioticassociated diarrhea from various hospital surroundings, have been compared. The results were conclusive in that nisin was evidently the most effective of the three antimicrobials tested. Nisin provided an overall MIC 90 of 0.256mg/L while both vancomycin and metronidazole had MIC 90 of 0.8mg/L [177] . The success of nisin supports previous agar dilution based assays which established that nisin effectively inhibited five clinical isolates of C. difficile [178] . In this instance, MIC values between 0.125μg/mL to 2μg/mL were obtained. Another benefit of the use of nisin as an anti-C. difficile agent is that its ability to inhibit spore germination could lower the incidence of relapse which is caused as a result of spore persistence in the gastrointestinal tract of patients from unsuccessful antibiotic treatments.
Lantibiotics are generally regarded as possessing poor anti-Gram negative activity. This insensitivity is thought to due to an inability to passage across the outer membrane of the Gram-negative cell wall, thus limiting access to lipid II [95] . However this general trend is not always strictly true. In fact it has been established that, in its purified form, nisin Z exhibits activity against other Gram negative microbes such as Escherichia coli (active at 600nM, though less active in the presence of NaCl; [179] ). Purified nisin Z generated an MIC of 75nM against S. aureus while the unpurified peptide produced an MIC of 1 M indicating a 13 fold increase in activity when peptide is purified. The activity of nisin against some Gram negative bacteria may as a result of a phenomenon whereby some cationic peptides can cross the outer membrane of Gram negative bacteria via the self-promoted uptake pathway [180] . In such situations the peptide binds to the surface lipopolysaccharide (LPS) with high affinity causing the displacement of divalent cations and destabilizing the Gram negative outer membrane resulting in channel formation in the cytoplasmic membrane and ultimately cell death [181, 182] . There is further evidence of the success of nisin in targeting Gram negative bacteria. Both nisin A and Z exhibited activity against two antibiotic resistant strains of Neisseria gonorrhoeae [166] and the anti-Helicobacter pylori data provides cause for optimism. H. pylori is the causative bacteria of gastritis and peptic ulceration [183] . The associated drug treatments, consisting of a mixture of antibiotics including amoxicillin, ampicillin, erythromycin, clarithromycin or metronidazole, which are administered to patients suffering with peptic ulcers have, in the past, been the source of adverse side effects in humans and hence their future use is questionable. The situation has been further complicated by the emergence of antibiotic resistant mutants [184] [185] [186] and the limited selection of alternative antibiotics that could be applied as a consequence of pH instability issues [184] [185] [186] . Given the effective nature of nisin A and Z, combined with the fact that nisin A is particularly resistant to acidic pHs, these lantibiotics may prove to be suitable alternatives to the conventional antimicrobial treatments [166, 187, 188] . Another Gram negative bacteria that has shown susceptibility to nisin, whether alone or in combination with other antimicrobials, is Pseudomonas aeruginosa [189] . P. aeruginosa is a clinically important pathogen because of its natural resistance to many antimicrobial agents. It produces high rates of both morbidity and mortality as a result of developing resistance during drug therapy. As a result of this, it continues be a major hurdle in the hospital environment [189] . It has been suggested that the best approach to overcoming resistant P. aeruginosa may be through combination therapy. Combination therapy is used to increase the in vivo activity, to avoid the emergence of drug resistance and to broaden antimicroabial spectrum [190, 191] . Giacometti et al. tested 40 clinical isolates of P. aeruginosa with 5 cationic peptides, including nisin, alone or in synergy studies with 9 clinically used antimicrobial agents. Synergy was observed when nisin was combined with polymyxin E and clarithromycin [189] . The MIC range of nisin against the 40 clinical isolates was 8-128 mg/L. Nisin (32 mg/L) also killed exponentially growing bacteria within a 40 minute exposure time.
Combination therapy is also being investigated as an alternative to the targeting of Gram positive pathogens. The in vitro activity of nisin alone and in combination with bacitracin, ramomplanin and chloramphenicol against twenty VRE strains and MRSA strains has been tested [192] . When used alone, nisin MICs ranged between 2 and 16mg/L for MRSA strains with an MIC 90 of 12mg/L and in the case of VREs MIC values ranged between 1.5-16mg/L with an MIC 90 of 8mg/L [192] . Although chloramphenicol antagonized the activity of nisin against 19 of the twenty MRSA strains, a two way synergy existed between nisin and chloramphenicol for nine VRE strains ( FIC min 0.21-0.58). Furthermore, nisin and ramoplanin functioned synergistically against both MRSA and VRE strains with a two way synergy evident with respect to 14 of the MRSA strains ( FIC min 0.37-0.63) while 12 VRE strains showed low level synergy ( FIC min 0.38-0.69). Time kill studies were carried out on all 20 of the MRSA strains and 4 of the VRE strains using MIC concentrations. With respect to 16 of the 20 MRSA strains tested, viable counts decreased from 10 6 to <300/mL within 2 hours, while nisin treatment resulted in a 3-log kill of VRE within one hour at MIC concentrations and rapid killing was also reported at concentrations <MIC [192] . In another study, the sensitivity of 40 MRSA hospital isolates, obtained from bodily fluids such as blood, pus, synovial fluid, and sputum from patients over a five year period, to nisin, alone and in combination with amoxicillin, amoxicillin-clavulanate, imipenem, clarithromycin, ciproflaxin, rifampin and vancomycin, was assessed [189] . MIC studies were performed using the microbroth dilution method. Rapid killing was observed when nisin was employed as complete inhibition was observed after an exposure period of 20 mins at a concentration of 32μg/L. The study also showed that when nisin was combined with the majority of other agents a 100-fold increase in kill was apparent after 24 hours, the exception being nisin/ -lactams combinations where no synergy was observed. The lack of synergy with -lactams proved to be an MRSA specific phenomenon as synergism was evident when methicillin-sensitive strains were targeted.
Epidermin-Like and Pep 5-Like Peptides
Although structurally unrelated, the epidermin-and Pep 5-like peptides have both been the subject of studies investigating their potential as anti-staphylococcal antimicrobials. In one such study, the activity of Pep5 and epidermin was tested against sixteen S. aureus strains, of which 10 were MRSA, and 57 CNS strains. Sensitivity to the bacteriocins was tested using a method similar to the deferred antagonism test [193] and was repeated at least twice for all strains. The results were conclusive in that Pep5 and epidermin showed significant activity against strains of a methicillin resistant nature, inhibiting 87.5% and 81.3% respectively. With respect to the nosocomial CNS strains it was established that Pep5 inhibited the majority (77.2%), including 19 of 25 strains that were resistant to either methicillin or mupirocin. In fact when S. haemolyticus strains are removed from this statistical analysis the % inhibition value increases to 90%. The activity of Pep5 against four out of five CNS strains that were especially highly mupirocin resistant was particularly notable [194] . Epidermin was less effective against CNS in general, displaying activity against 23 of the 57 strains (40.4%). This correlates with another study [195] which established that while epidermin inhibited all CNS strains associated with bovine mastitis, its success rate with respect to clinical CNS strains was lower at 40%. This data encourages the potential use of Pep5 against methicillin and mupirocin resistant strains that continue to colonize and infect patients following the failure of standard treatments [196] .
Following from these positive results, both Pep5 and epidermin have been investigated with a view to assessing their ability to inhibit catheter colonization by CNS [14] . It was established that the addition of Pep5 or epidermin to test catheters resulted in a decrease in bacterial adhesion compared with untreated controls [14] . Both of the lantibiotics were effective even when added after initial colonization, indicating a rapid antimicrobial action. This would imply that Pep5 or epidermin could be applied upon placement of the catheter and could perhaps be applied repeatedly while the device is in place. External and internal impregnation of catheters with the lantibiotics would have to be considered as previous studies using catheters impregnated on the outside only were not very effective [197, 198] . Given that the two lantibiotics, Pep5 and epidermin, brought about a considerable decrease in bacterial cell adherence to catheters, it would seem likely that further investigations could be highly rewarding. Finally, although it has also been shown that epidermin is active against N. gonnorrhoeae and M. smegmatis [166] , additional investigation would be necessary before its genuine clinical potential as an antiNeisseria or anti-Mycobacterium agent could be assessed.
Mutacins
Bacteriocins produced by S. mutans are termed mutacins [199] [200] [201] [202] [203] . Many of these are lantibiotics but differ from one another in that they are representative of different lantibiotic subgroups. Significantly, with respect to this review, antimicrobial activity against clini-cally relevant pathogens has been noted on a number of occasions. The epidermin-like mutacin B-Ny266, which differs from epidermin with respect to seven amino acids [201] was found to be active against a wide range of Gram positive pathogens including Actinobacilli, Bacilli, Clostridia, Corynebacteria, Enterococci, Listeriae, Mycobacteria, Neisseriae, Staphylococci and Streptococci [200, 203] . It is closely related to another mutacin, 1140 (also known as mutacin III), differing by only two amino acids and sharing a 94% similar activity spectrum [166] . The activity of Ny266 against Enterococci, Listeriae, Staphylococci, Streptococci, Bacilli, Clostridia and Mycobacteria has also been compared with that of nisin A and the antibiotics vancomycin and oxacillin [188] . Here Ny266 consistently outperformed nisin A. It was established that the nisin A MICs ranged from 8.4-33.4 g/ml for 12 enterococcal strains while B-Ny266 was slightly more active yielding results of 1.6-25.6 μg/ml. For 23 Listeria strains, MIC values for nisin were between 1.1 and 16.7 μg/ml while B-Ny266 values were lower at 0.4-2.0 μg/ml. This level of activity is comparable with that of vancomycin and is greater than that of oxacillin (0.5-15.9 μg/ml). MIC determination studies with nineteen strains of staphylococci (including S. haemolyticus, S. epidermidis, S. gallinarum, S. saprophyticus and S. xylosus and seven strains of S. aureus), Gram positive spore forming bacilli, Campylobacter jejuni, H. pylori, and Neisseria spp established that the activity of B-Ny266 was equal or greater than that of nisin, oxacillin and vancomycin [188] . As part of a pre-clinical evaluation of B-Ny266, Mota-Meira et al. tested the in vivo activity of B-Ny266 against S. aureus (MSSA) using a mouse model infection [204] . The mouse was intraperitoneally infected and then immediately treated with a single dose of intraperitoneally administered B-Ny266 [204] . No mortality was noted in the mutacin-treated mice and the three dose concentrations administered, 1, 3 and 10mg/kg, were protective. The ED 50 dose of B-Ny266, <1mg/kg, was comparable to that of vancomycin Little is known about the toxicity of mutacin B-Ny266 however, in this study, injection of 10mg/kg of the mutacin did not appear to affect the health of the mice.
Mersacidin/Actagardine Like Peptides
The in vitro activity of mersacidin against staphylococci is not particularly impressive, being four-to eight fold less active than vancomycin, daptomycin, or teicoplanin [205] . This was most evident in the case of methicillin resistant strains where, in some cases, MICs were 32 g/ml, while 90% of the methicillin sensitive S. aureus and S. epidermidis strains were relatively tolerant with MIC values of 8 g/ml. To compound this, mersacidin demonstrated lower in vitro activity than the other antimicrobials against hemolytic streptococci where 8 g/ml was required to inhibit 90% of Group B, C and G streptococci whereas the levels of other antimicrobials required to have a similar impact were 0.5-1μg/ml. Mersacidin was also especially ineffective against E. faecalis (MIC of 64 g/ml) [205] . However, mersacidin compensates for its relatively unremarkable in vitro activities by displaying in vivo levels (mouse models) of activity [206] . In a study by Chatterjee et al., the in vitro activity of mersacidin was again assessed but on this occasion its in vivo effectiveness was also investigated and compared to that of erythromycin and vancomycin. In vitro, mersacidin inhibited 50% of the methicillin sensitive S. aureus strains tested at a concentration of 5 g/ml whereas the corresponding values for vancomycin and erythromycin were 0.3 g/ml and 0.2 g/ml respectively [206] . For coagulase negative Staphylococci, an MIC of 32 g/ml compared unfavorably with values of 0.5 g/ml and 0.2 g/ml for vancomycin and erythromycin, respectively, and its poor activity against enterococci was confirmed (MIC values between 16 and 128 g/ml). In contrast, however, the activity of mersacidin was much greater when assessed in vivo. In fact, the effective dose (ED) values for mersacidin are lower than those for vancomycin with respect to the MRSA strain S. aureus E 710 i.e. mersacidin ED 50 50 and 90 denote the minimum dose required to cure 50% and 90% of the infected animals, respectively). Kruszewska et al., also carried out an in vivo study evaluating the use of mersacidin as a therapeutic compound against MRSA harboured in the nasal carriage of humans [207] . This study was prompted by studies linking the asymptomatic nasal carriage of S. aureus by healthy individuals with a greater likelihood of developing severe staphylococcal associated diseases [208] [209] [210] . Although, nasal carriage of MRSA has routinely been addressed with multiple applications of the topical agent mupirocin [211] , re-colonization has been reported after 6 months in nearly 67% of patients [212, 213] . The future use of mupirocin in the clinical environment has also been questioned for other reasons [214, 215] . More specifically, although, mupirocin is frequently used as to prevent staphylococcal colonization of implanted medical devices, and catheters in particular [216] , and its use has been proposed as a prophylactic measure to avoid MRSA colonization due to invasive surgeries [217] , prolonged clinical use has lead to increasing resistance. It is thus particularly pertinent that mersacidin, when administered intranasally twice daily (1.66mg/kg per treatment) over 3 days, successfully eradicated the MRSA from the nasal mucosa of colonized mice. Furthermore merascidin continued to be effective even when MRSA-induced rhinitis was established over a greater period i.e. three inoculations over 5 days or six inoculations after 30 days. Such promising results advocate further research into the use of mersacidin as an antimicrobial agent.
Planosporicin
Recently the discovery of a new Planomonospora sp produced lantibiotic, planosporicin, has been identified, which inhibits bacterial peptidoglycan synthesis [218] . Due to similarities with respect to mode of action and globular structure, it falls into the mersacidin-like subgroup of lantibiotics. Depsite these functional similarities, planosporicin does not contain any conserved motif resembling mersacidin or actagardin. However, its initial NH 2 sequence of three amino acids (NH2-Ile-Dhb-Ala) is identical to that of nisin [218] . As this region is essential for nisin binding of the lipid II pyrophosphate region, it may be that it has the same function in planosporicin. Planosporicin has a molecular weight of 2194 Da and comprises 24 amino acids. It was identified as part of a strategy whereby 120,000 microbial extracts from 40,000 actinomycetes were screened for antimicrobial activity against a S. aureus strain by means of a liquid microtitre assay. Secondary selection for antimicrobial activity was based on whether any antimicrobial activity present was reversed by the addition of alactamase cocktail or by adding D-Ala-D-Ala affinity resin [219] . The majority of extracts selected during primary screening were then dismissed because their activity was as a result of -lactams susceptible to -lactamases or to D-Ala-D-Ala binding glycopeptides. Other extracts were also discarded because of the lack of novelty after lipid chromatography coupled to mass spectrometry (LC-MS) analysis or because they did not give dependable and reproducible results upon repeated fermentations of the producing strains [218] . Lantibiotic molecules were found in 35 broth extracts according to their LC-MS profiles accompanied with bioautography and by looking for Lan and MeLan amino acids in the acid hydrolysates of the crude extracts. Of these 35 lanthionine containing molecules, actagardine [220, 221] was recurrently identified. Apart from actagardine, a total of five distinct lantibiotics, whose chemical properties were different to any other known microbial metabolite, were distinguished. Among these was planosporicin produced by the uncommon actinomycete Planomonospora sp. [218] . The structure of planosporicin was elucidated by nuclear magnetic resonance spectroscopy (NMR) and then purified. Production of planosporicin was observed 48 hours after inoculation and the majority of the antibiotic (90%) was secreted into the broth. When tested using broth microdilution method, Planosporicin was found to be active against MRSA and VRE with MIC values of 8-16 g/ml and 16-128 g/ml, respectively. These values are superior to that of actagardine and similar to values obtained for mersacidin. Planosporicin is stable and soluble at physiological pH. In a mouse model testing murine septicaemia induced by Strep. pyogenes, planosporicin showed good efficacy after a single dose and no acute toxicity was observed up to 100mg/kg. Lactobacilli, including strains that were implicated in clinical bacteremia or endocarditis [222] , also showed great sensitivity to planosporicin yielding (MIC values 0.5-64 g/ml) while MIC values of 0.25 μg/ml for clostridia were particularly impressive when one contrasts these with the corresponding actagardine and mersacidin values i.e. 4 g/ml and 8 g/ml, respectively
Lacticin 3147
Given the activity of the mersacidin-like peptides, it would seem logical that, as a consequence of their added ability to bring about pore-formation, the two peptide lantibiotics which consist of one mersacidin-like peptide, possess at least as much, if not more, potential. Of these, lacticin 3147 has been investigated in great depth. When first isolated it was established that lacticin 3147 has a broad spectrum of activity, being capable of inhibiting the growth of a wide range of food-borne bacteria [106] . During initial studies it became apparent that unlike nisin, which is less active at physiological pH, lacticin 3147 is soluble and active at physiological pH, thus further strengthening its candidacy as an antimicrobial for human clinical applications. A study carried out investigated the effect of lacticin 3147 against pathogenic Gram positive bacteria [223] including MRSA, VRE, and penicillin resistant Pneumococcus (PRP), Propionibacterium acne and Streptococcus mutans. The pathogens used for this study represent organisms with different sites of infection (e. g. respiratory, meningial, skin, oral, wound and cardiac). Although lacticin 3147 showed no apparent activity against one MRSA strain in an agar well diffusion assay with a lacticin 3147 preparation of 20,000 AU/ml, the results obtained from time kill curve studies (using the same concentration of lacticin 3147) established that there was a significant inhibitory effect. When vancomycin resistant E. faecalis and penicillin resistant pneumococci were exposed to this level of bacteriocin, an even more rapid killing effect was noted with no survivors being detected after 30 minutes while S. mutans cells died after 90 minutes. The most sensitive of all the test strains was Propionibacterium acne with no survivors detected after 1 minute of the addition of the antimicrobial. Further studies, including trials with purified lacticin 3147 and the determination of its activity in serum and topical creams are necessary to evaluate the potential application of lacticin 3147 as an alternative therapeutic compound.
The activity of lacticin 3147 against C. difficile is a particular cause for optimism. The sensitivity of genetically distinct C. difficile strains was first assessed by isolating strains (from stool samples) from patients suffering from a variety of clinical conditions and as well as from healthy individuals [224] . Eight strains were collected in total consisting of five from patients with CDAD, two from patients with inflammatory bowel disease and one strain from a healthy individual. MIC 50 values for lacticin 3147 indicate that it compares well with the routinely used antibiotics with a value of 3.6μg ml -1 compared to an MIC range of 0.5-4.0μg ml -1 for metronidazole and vancomycin. When exposed to 6 μg lacticin ml -1 , representative toxin positive and negative strains were eliminated after 20 and 120 minutes respectively. This kill also manifested itself as a clearing of broth over time [224] . Rea et al. also investigated the influence of lacticin 3147 on commensal gut microbiota using an anaerobic faecal-based fermentation. While lacticin 3147 did not appear to have an effect on non-spore forming anaerobes, non-spore forming aerobes or Bacteroides sp., Gram positive organisms such as Enterococci, Bifidobacteria and Lactobacilli were greatly reduced i.e. there was a 4 log reduction after 90 minutes upon exposure to lacticin 3147 at 74μg ml -1 . A similar negative effect on intestinal Gram positive commensals was also observed with nisin A and nisin Z, especially upon Bifidobacterium bifidum [225] . A lower concentration of 19μg lacticin ml -1 was still sufficient to reduce C. difficile below detectable levels after 30 minutes, while having a less severe on other elements of the gut flora i.e. a 2 log cycle reduction of the lactobacilli and bifidobacterium. Results from this study are encouraging and would support further investigation of the use of lacticin 3147 as an anti-C. difficile agent. It should be noted however that due to the possibility of proteolysis lantibiotics like lacticin 3147 may not be able to endure gastric transit and so encapsulation would need to be employed for oral administration in order for the antimicrobial to reach the desired target site. Alternatively, administration via the anal route could be employed. It would also be possible to compensate for the negative effects on the gut microbiota through the use of probiotic strains that have been made resistant to lacticin 3147.
A related lantibiotic, staphylococcin C55, was initially partially purified from cultures of S. aureus C55 [226] . Crude assays established that it inhibited 21 of the 31 S. aureus strains tested but did not inhibit any of 18 strains of S. epidermidis tested [226] . Upon their ultimate purification the two components were named C55 and C55 and were found to have molecular weights of 3339 and 2993, respectively and their activity was further assessed by means of the deferred-antagonism test. C55 showed a promising ability to inhibit 120 strains of S. aureus including strains that were mupirocin and methicillin resistant and only 2 S. aureus strains appeared to be resistant. It was established that these strains are most likely to be resistant because of also being C55 producers, and thus possessing an innate immunity against the lantibiotic [107] . Yet again, CNS strains were found to be resistant however. When the extent of the close relatedness of staphylococcin C55 and lacticin 3147 was discovered (86% (Ltn and C55 ) and 55% (Ltn and C55 ) identity), it was postulated that it may be possible to combine individual components from each lantibiotic. This was successfully achieved as the hybrid peptide pairs of Ltn : C55 and C55 : Ltn were found to have activity in the single nanomolar range, thus comparing well with their native pairings [227] . It may thus be possible to generate novel lantibiotics through combining the individual components of a selection of related but different two component lantibiotics.
Another two component lantibiotic that may be of medical significance is haloduracin, produced by a Bacillus halodurans [108, 109] . Its two peptides, namely Hal (modified)/A1 (unmodified) and Hal (modified)/A2(unmodified), have molecular masses of 3044 and 2331 Da respectively as determined by mass spectrometry [109] . Bacillus sp. are known providers of antimicrobial peptides having already given us lantibiotics such as sublancin, subtilin, ericin A and S, and mersacidin. [146, 228, 229] . Despite this variety of lantibiotics, no examples of two component peptides have been encountered to date in this species [109] . Bacillus halodurans C-125 is an aerophillic, akaliphillic Gram positive bacterium that was originally isolated from soil [230] . The antimicrobial activity of haloduracin was assessed by well diffusion agar assays and deferred antagonism assays and it was established that many lactococci and representative Listeria, Streptococcus, Enterococcus, Bacillus and Pediococcus species were sensitive to the antimicrobial [109] . These preliminary results would require further studies and support the potential application of haloduracin against Gram positive pathogens such as Enterococcus sp.
Bioengineering of Lantibiotics
Many strategies have been employed with the aim of improving the therapeutic potential of lantibiotics [102] . As lantibiotics are geneencoded peptides one such approach has been to generate derivatives through mutagenesis of the structural gene of the precursor peptide with the logic being that these derivatives could be superior to the wild type lantibiotics itself, i.e. be active across a broader pH, and have improved stability or ability to bind to cell targets, with the ultimate view being to generate novel lead compounds for drug development. While site-directed approaches have dominated to date, random mutagenesis strategies could yield a huge number of derivatives. Despite this great potential, no lantibiotic derivatives have been generated which have merited development as lead compounds as clini-cal antimicrobials. One of the factors that has restricted rational lantibiotic design has been a lack of in-depth knowledge with respect to the role of individual motifs and amino acids within the peptides [103] . It is hoped that the dramatic recent improvement in our understanding of these peptides, and the biosynthetic machinery responsible for their synthesis, will lead to the creation of tailor-made lantibiotics and an ability to enhance the activity/stability of existing drugs through the incorporation of lantibiotic-associated features.
During the 1990s the first generation of lantibiotic derivatives was created through genetic manipulation of the structural peptide. Given the emerging nature of this technology it is not surprising that, although a number of mutants were generated that were scientifically interesting (see [102] for review), major developments with respect to generating derivatives with enhanced activity did not result. The most notable successes involved mutation of glutamate 4 (Glu4) of the nisin-like peptide subtilin to isoleucine, i.e. the residue at the corresponding location in nisin, to reduce the extent to which the adjacent residue (Dha5) undergoes an activity-reducing self-modification. This derivative possessed approximately 3-4 fold higher activity than the natural peptide and a 57-fold increase in chemical and biological stability. The manipulation of the Dha5 residue in nisin has had some positive consequences in that although the conversion of Dha5 of nisin to a Dhb residue (through replacing a serine with a threonine in the unmodified peptide) lowers the antimicrobial activity of the peptide [100, 231] , it has considerably greater resistance to acidcatalyzed chemical degradation than wild-type nisin Z [231] . Similarly the solubility of nisin at neutral pH has been enhanced through mutagenesis. This is significant as the solubility of nisin A is highest at low pH (pH 3) and gradually decreases by nearly 2 orders of magnitude when the pH of the solution exceeds a value of 7. At low pH, nisin Z has decreased solubility relative to the A variant while at neutral and higher pH values, their solubilities are similar. The two nisin mutants with enhanced solubility (by 4 and 7 fold at neutral pH) both contained additional lysyl residues which were incorporated at positions 27 and 31 respectively, to yield N27K and H31K. Significantly, their antimicrobial activities were comparable to that of nisin Z. There was also a positive impact with respect to freeze drying, a condition that mimics extreme low pH (<2) stress in that while repeated freeze drying of nisin Z resulted in a complete loss of activity, the loss of the Dha5Dhb mutant activity was negligible. This finding would suggest the importance of Dha in the inactivation of nisin at a low pH [231] .
Interestingly, site-directed mutagenesis of nisin has also revealed that it may be possible to modulate the antimicrobial activity of nisin, with respect to particular target organisms, by genetic engineering as although a nisin mutant containing G18T/M17Q was approximately 4 fold less active than nisin against B. cereus and S. thermophilus, it proved to be twice as active as the wild type nisin against M. flavus [100] .
Gallidermin and epidermin have also been the subject of mutation [232] with, in this case, the focus being on the generation of derivatives with enhanced resistance to trypsin. Hence, the creation of mutants that were resistant to proteases and possessed high antimicrobial activity were preferable. There were partial successes in that Dhb14Pro and Ala12Leu showed increased resistance to trypsin but unfortunately the antimicrobial activity of these peptides was also diminished. Future studies, involving the creation and analysis of a larger selection of hinge region mutants, could reveal alterations resulting in enhanced protease resistance without the accompanying detrimental impact on bioactivity.
In recent years researchers, armed with an enhanced understanding of how the mode of action of lantibiotics, have shown a renewed interest in the generation of lantibiotic derivatives. Targeting of the hinge region of nisin has further emphasized the fact that the activity of the antimicrobial against specific target strains can be enhanced i.e. the hinge mutants N20K and M21K display enhanced activity against Shigella, Pseudomonas and Salmonella species and these mutants were also found to be more soluble than wild-type nisinZ [233] . Additional hinge mutants i.e. N20Q and M21G were also identified which were more stable than nisin Z at high temperatures and at neutral or alkaline pH [233] . Randomization of three N-terminal residues of nisin i.e. Ile4, Ser5, and Leu6 has also resulted in the generation of a number of interesting derivatives. The mutant KFI was more active than wild type nisin A against L. johnsonii (10-fold lowered IC 50 ) and L. mesenteroides (9-fold lowered IC 50 ). The purified KSI mutant showed a 1.6 and 2-fold higher activity against indicators L. lactis and L. johnsonii compared to nisin but was 2-fold less active against S. epidermidis and P. pentosaceus. The KFI and KSI mutants also demonstrated an enhanced ability to prevent spore outgrowth [234] .
The use of site-directed mutagenesis has also been applied to lacticin 3147 for the first time recently. To facilitate the ultimate generation of rationally designed mutants with enhanced activity two approaches, complete alanine scanning and random mutagenesis, were taken to reveal residues/domains within the Ltn and Ltn peptides which may be tolerant of change. It was established that 36 of the 59 amino acids present in the two peptides retained at least some activity following conversion to alanine, highlighting an attribute, i.e. a tolerance of change, that will be greatly beneficial with respect to the further derivatization of the peptides [103] . This flexibility was further emphasized from corresponding random mutagenesis approaches [235] .
Another biologically-based approach to generating lantibiotic derivatives, or indeed peptides with lantibiotic-like features, is the utilization of lantibiotic biosynthetic enzymes, in vivo and in vitro [236] . The benefit of introducing lanthionines into non-lantibiotics has been apparent from studies establishing that synthetic lanthionines have use as mimics of disulfides or as structures that restrict the conformational flexibility of bioactive compounds [237] . Such lanthionine moieties can provide superior chemical, proteolytic and metabolic stability to such derivatives [238] [239] [240] . Thus these biologically advantageous properties may be the backbone for the design of new therapeutic peptides containing these cyclic lanthionines [241] . The incorporation of such amino acids in vivo into peptides is very challenging and is restricted to peptides that contain proteinogenic amino acids. Nonetheless there have been successes, for example posttranslational modification of NukA residues by the nukacin ISK-1 modification enzyme has been reconstituted in E. coli [236] while fusion of the nisin leader peptide to short non-lantibiotic peptides in L. lactis has revealed that these too can be modified by the nisinassociated dehydratase (NisB) and cyclase (NisC) enzymes [234, 242, 243] . Lantibiotic biosynthetic enzymes show even greater flexibility when applied in vitro, although it should be noted that this benefit is tempered by the limited quantities of end product which result. The successes in this area include the establishment that the biosynthetic enzyme of lacticin 481, LctM, has a broad substrate tolerance [241] while the activities of epidermin [136] , mersacidin [244] , nisin [245, 246] and haloduracin [108] biosynthetic enzymes have all been reconstituted in vitro.
These biological approaches have been taken as a consequence of the difficulties associated with the synthetic generation of lantibioticlike compounds. However, it should be noted that there have been some successes in this areas as total synthesis of nisin A has been performed [247] and more recently modified lantibiotic like peptides have been generated using different chemical approaches [237, [248] [249] [250] [251] [252] [253] .
CONCLUSIONS
Throughout this review the evidence that lantibiotics could be successful in a clinical setting has been highlighted. Lantibiotics are effective against numerous clinically important pathogens and the fact that many do so via a novel and previously unexploited mode of action is ideal as it overcomes the problem of pre-existing resistance mechanisms, the emergence of which have made the identification of novel antimicrobials an ever more pressing issue. In addition to the lantibiotics that researchers have been aware of for quite some time, new lantibiotics, and with them new structural elements and functionalities, continue to be revealed. Indeed the fact that the strategies used to screen for novel lantibiotics have become more technologically advanced enhances the chances of success. Logically, the greater the number of microorganisms assessed, the greater the likelihood of discovering novel lanthionine-containing peptides. Therefore, the scaling up of screening protocols is of key importance. A recent example of such an approach involved screening to identify cell wall inhibitors other than the clinically applied cell wall-acting antimicrobials (such as the -lactams and glycopeptides) that have previously been isolated from actinomycetes [218] . On this occasion a library of 120,000 broth extracts was screened by fermenting 40,000 actinomycetes isolated from the environment. The majority of the isolates screened belonged to uncommon genera indicating that they are not easily isolated or cultivated and therefore had never been previously used for industrial research. As a result of this method and the vast number of isolates screened, five new lantibiotics were discovered. Genome sequencing has and will also continue to contribute to the discovery of novel lantibiotics and provide a better knowledge of their regulatory mechanisms, thereby also facilitating overproduction. An alternative approach to accessing novel/improved lantibiotics involves the derivitization of existing lantibiotics. As we have highlighted, lantibiotics are synthesized on the ribosome and are amenable to rational drug design. Thus protein engineering strategies can be adopted by which existing lantibiotic structures are used as a blueprint to create peptides with improved biological activity and/or a wider spectrum of inhibition. Similarly lantibiotic peptides can be the subject of chemical modification and even more recently, lantibioticassociated biology (in vitro utilization of enzymes) and chemistry have been applied to non-lantibiotic drugs of medical relevance. Thus in addition to the lantibiotics of medical significance that have been identified to date, improved screening and peptide derivitization/bioengineering strategies promise to greatly extend the clinical usefulness of these powerful antimicrobial peptides.
NOTES ADDED IN PROOF
A new lantibiotic, microbisporicin, with significant levels of activity against a number of significant pathogens has recently been identified [Castiglione, F., Lazzarini, A., Carrano, L., Corti, E., Ciciliato, I., Gastaldo, L., Candiani, P., Losi, D., Marinelli, F., Selva, E., Parenti, F. Chem Biol. 11(1), 22, (2008) ].
